CD274 and neoplasm: Multiple phase 3 randomized trials, including Checkmate 141, Keynote-040, and Keynote-048, all achieved satisfactory efficacy, especially for patients with PD-L1 tumor proportion score (percentage of tumor cells with membranous PD-L1 expression) ≥50% or PD-L1 combined score (CPS) ≥1% (21–23).